Selvigaltin (GB1211) is the first small-molecule, orally delivered galectin-3 inhibitor to be discovered. It is developed by Galecto Biotech, which is testing the molecule to see if it reduces decompensated cirrhosis and resistance to checkpoint inhibitors (a type of anti-cancer drug).